HME improves drug solubility and bioavailability through molecular-level API dispersion.
It also prevents thermal and mechanical degradation during processing.

PureMelt™ addresses poor drug solubility and formulation instability associated with conventional processing methods. It ensures better bioavailability and formulation stability, while also resulting in a better impurity profile of the ASD.

HME and TSG enable a smooth transition from R&D to commercial manufacturing. Their continuous processing systems ensure scalable production and consistent product quality.

Continuous manufacturing improves product consistency and reduces variability compared to traditional batch processes. It also enables more efficient, scalable, and sustainable manufacturing.